SCHEMBL5387612

SCHEMBL5387612

CCOC(=O)C(OC)C(O)c1ccc(OCc2ccccc2)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
FFAR1 O14842 2/20 0.47
PPARG P37231 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HSP90AA1 P07900 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
MRGPRX4 Q96LA9 3/20 0.42
MAOB P27338 2/20 0.42
LTA4H P09960 1/20 0.42
S1PR1 P21453 1/20 0.41
PRKX P51817 1/20 0.41
ACVR1 Q04771 1/20 0.41
S1PR5 Q9H228 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370006 0.86 FFAR1 (0.51) LMNAL3MBTL1FFAR1PPARGALDH1A1
SCHEMBL5015936 0.80 LMNA (0.52) LMNAL3MBTL1FFAR1PPARGALDH1A1
SCHEMBL3372084 0.79 LMNA (0.51) LMNAL3MBTL1FFAR1PPARGALDH1A1
SCHEMBL5387074 0.79 LMNA (0.51) LMNAL3MBTL1PPARGALDH1A1MEN1
SCHEMBL3373966 0.76 LMNA (0.47) LMNAL3MBTL1FFAR1PPARGALDH1A1
SCHEMBL3373968 0.76 LMNA (0.47) LMNAL3MBTL1FFAR1PPARGALDH1A1
SCHEMBL3369977 0.76 LMNA (0.47) LMNAL3MBTL1FFAR1PPARGALDH1A1
SCHEMBL5017527 0.76 LMNA (0.53) LMNAL3MBTL1FFAR1PPARGALDH1A1
SCHEMBL3371171 0.74 LMNA (0.53) LMNAL3MBTL1PPARGALDH1A1MEN1
SCHEMBL2861613 0.74 MEN1 (0.62) LMNAL3MBTL1PPARGALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 US disclosed
EP-1392637-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2004-03-03 EP disclosed
WO-2002100813-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA LMNA 3747/4885L3MBTL1 3898/4885FFAR1 59/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA LMNA 4004/4885L3MBTL1 3481/4885FFAR1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.